Former Principal, Sofinnova Partners
Sara Núñez-García most recently served as a Principal with Sofinnova Partners, focusing on investments in the biopharmaceutical sector. Sara was involved in various investments such as Delinia Bio (sold to Celgene), ProQR Therapeutics (PRQR), Auris Medical (EARS), MedDay Pharma, ObsEva (OBSV), Enyo Pharma and Asceneuron. She is a board observer in Enyo Pharma and previously in Delinia Bio. In addition, she serves as an expert reviewer for the NIH.
Prior to joining Sofinnova Partners in 2013, Sara was an associate in the Licensing and M&A team at Onyx Pharmaceuticals (now Amgen) in California, where she proposed option-based and structured deals for various potential acquisitions in the oncology space.
Sara spent six years in the pharmaceutical industry with Solvay and Abbott Laboratories in The Netherlands as a Medicinal Chemist. During her time in drug discovery, Sara worked on preclinical programmes for central nervous system indications, contributing to the submission of several IND packages.
Sara was a postdoctoral fellow in the Biochemistry and Biophysics departments at the Albert Einstein College of Medicine in New York where she developed several transition state inhibitors for oncology targets. She received her PhD in Chemistry from the University of Manchester, UK. Sara has published eighteen peer-reviewed articles and patents. In addition, Sara also holds an MBA from INSEAD.